12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Northera droxidopa regulatory update

Chelsea unveiled details of FDA briefing documents the company received ahead of this month's advisory panel meeting to discuss an NDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). According to Chelsea, the documents included...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >